The global precision oncology market size is estimated at USD 120.97 billion in 2024, grew to USD 133 billion in 2025 and is predicted to surpass around USD 312.33 billion by 2034, expanding at a CAGR of 9.95% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Precision Oncology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Precision Oncology Market, by Product, 2024-2034
8.1.1 Diagnostics
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Therapeutics0
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Precision Oncology Market, by Cancer Type, 2024-2034
9.1.1. Breast cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Colorectal cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Lung cancer
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Blood Cancer
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. Precision Oncology Market, by Cancer Type, 2024-2034
10.1.1. Pharmaceutical & Biotechnology Companies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Hospitals & Diagnostic Laboratories
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Healthcare Data Companies
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Invitae Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Illumina, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Myriad Genetics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Rain Oncology Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Strata Oncology, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Repare Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Relay Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Exscientia
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample